Alimera Sciences Overview

  • Founded
  • 2003
Founded
  • Status
  • Public
  • Employees
  • 140
Employees
  • Stock Symbol
  • ALIM
Stock Symbol
  • Share Price
  • $4.29
  • (As of Friday Closing)

Alimera Sciences General Information

Description

Alimera Sciences Inc is a pharmaceutical company focused on commercializing and developing treatments that address diseases affecting the back of the eye (retina). ILUVIEN is Alimera's a patented micro-implant which delivers a continuous, low dose anti-inflammatory agent to the retina for up to 3 years. DME is often treated with acute therapies when the fluid in the eye returns. ILUVIEN reduces the recurrence of edema to stable vision, with the benefit of continuous treatment due to the product's novel drug delivery technology. The company expects to accelerate growth of ILUVIEN through increased penetration of existing markets; expansion into new markets; and a new indication for non-infectious posterior uveitis in the EU.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Biotechnology
Stock Exchange
NAS
Primary Office
  • 6120 Windward Parkway
  • Suite 290
  • Alpharetta, GA 30005
  • United States
+1 (678) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Alimera Sciences Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$4.29 $4.55 $3.94 - $12.25 $31.6M 6.94M 62.7K -$0.22

Alimera Sciences Financials Summary

In Thousands,
USD
TTM 30-Sep-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018
EV 66,563 83,418 99,403 106,341
Revenue 58,844 50,820 53,943 46,599
EBITDA 7,187 2,649 (2,717) (8,856)
Net Income (1,243) (5,339) (10,443) (16,382)
Total Assets 60,065 50,855 50,309 54,108
Total Debt 43,127 45,017 39,476 38,414
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Alimera Sciences Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Alimera Sciences‘s full profile, request access.

Request a free trial

Alimera Sciences Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Alimera Sciences‘s full profile, request access.

Request a free trial

Alimera Sciences Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Alimera Sciences Inc is a pharmaceutical company focused on commercializing and developing treatments that address disea
Pharmaceuticals
Alpharetta, GA
140 As of 2020
00000
000000 - 000 00000

0000000

im ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequa
0000 000000000
Cambridge, United Kingdom
00 As of 0000
00.000
0000000000 0 00.000

00000000

henderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cup
000000000000000
Farmington Hills, MI
0 As of 0000
000.00
000000000 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Alimera Sciences Competitors (39)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Exonate Venture Capital-Backed Cambridge, United Kingdom 00 00.000 0000000000 0 00.000
00000000 000000 Formerly VC-backed Farmington Hills, MI 0 000.00 000000000 000.00
000000 00000000 Formerly VC-backed Palo Alto, CA 00 00000 00000000 00000
00000000 000000000 Corporation Watertown, MA 000 00000 000000000 00000
0000000 0000000000 Formerly VC-backed Redwood City, CA 000 00000 00000000000 00000
You’re viewing 5 of 39 competitors. Get the full list »

Alimera Sciences Patents

Alimera Sciences Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-3787749-A1 Methods of treating retinal diseases Pending 03-May-2018 000000000
US-20190336466-A1 Methods of treating retinal diseases Pending 03-May-2018 000000000 0
EP-2515911-A4 Method of reducing incidence of intraocular pressure associated with intraocular use of corticosteroids Withdrawn 23-Dec-2009 0000000000 0
US-20110150967-A1 Method of reducing incidence of intraocular pressure associated with intraocular use of corticosteroids Granted 23-Dec-2009 0000000000 0
US-20130156841-A1 Method of reducing incidence of intraocular pressure associated with intraocular use of corticosteroids Abandoned 23-Dec-2009 A61K9/0051 0
To view Alimera Sciences’s complete patent history, request access »

Alimera Sciences Executive Team (15)

Name Title Board Seat Contact Info
Richard Eiswirth Jr. Chief Executive Officer & Board Member
Philip Jones Chief Financial Officer
Philip Ashman Ph.D Chief Operating Officer, Operations & Senior Vice President
David Holland Chief Marketing Officer, Marketing & Founder
Philip Haldar Vice President & Marketing Director EMEA
You’re viewing 5 of 15 executive team members. Get the full list »

Alimera Sciences Board Members (18)

Name Representing Role Since
Calvin Roberts MD Self Board Member 000 0000
Garheng Kong Ph.D Self Board Member 000 0000
James Largent Alimera Sciences Board Member 000 0000
John Snisarenko Self Board Member 000 0000
Mark Brooks Self Board Member 000 0000
You’re viewing 5 of 18 board members. Get the full list »

Alimera Sciences Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Alimera Sciences Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Alimera Sciences‘s full profile, request access.

Request a free trial